Fierce Pharma
JANUARY 31, 2024
More than two years after Aduhelm's controversial and ill-fated FDA accelerated approval, Bi | Biogen is discontinuing its first Alzheimer's disease therapy, Aduhelm, after walking a rocky path. The company is taking a $60 million charge, halting sales and terminating a confirmatory trial.
MedCity News
JANUARY 31, 2024
We and our collective organizations’ providers have treated 10,000’s of Americans, who suffer from obesity and/or Type 2 diabetes with GLP-1 drugs. And we believe we have important observations to share.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Fierce Pharma
JANUARY 31, 2024
Beaten to the punch by Pfizer in developing a vaccine for COVID, GSK has regained some of its lost luster as a vaccine powerhouse with its advancement of respiratory syncytial virus (RSV) shot Arex | GSK's RSV vaccine Arexvy generated $1.5 billion in sales in 2023 compared to $890 million for Pfizer's Abrysvo. But the British pharma major says that the successful launch represents just one round of a boxing match, and much is still to be decided, especially with Moderna expected to joi
PharmaVoice
JANUARY 31, 2024
The president of L.A.’s City of Hope Cancer Center believes the current state of cancer treatments can be greatly improved with a peek into the gut’s many mysteries.
Advertisement
What if you could help your sellers stop wasting 72% of their day on non-selling activities and focus on bringing in revenue? Incorporating AI in your enablement workflows can help you cut down on busy work, get projects done faster, and let your team (and you!) focus on making a bigger impact. We put together this guide to show you how to use AI to cut time and costs for projects, including collateral creation, development of training videos, and automating tedious processes.
Fierce Pharma
JANUARY 31, 2024
After charting a series of sales increases in 2023, Teva’s largely made good on the promise of its new CEO’s “Pivot to Growth” campaign. | After charting a series of sales increases in 2023, Teva’s largely made good on the promise of its new CEO’s “Pivot to Growth” campaign. With group revenues on the up-and-up, it’s all about maintaining momentum in the years to come, the company’s chief executive Richard Francis said in an interview.
MedCity News
JANUARY 31, 2024
Biogen has returned its Aduhelm rights to Neurimmune, the company that initially developed the antibody Alzheimer’s disease drug. But Biogen isn’t abandoning Alzheimer’s, and its pipeline includes drugs that take other approaches to the neurodegenerative disorder.
Pharma Rep Focus brings together the best content for pharma rep professionals from the widest variety of industry thought leaders.
pharmaphorum
JANUARY 31, 2024
Novartis ends development of Tim3 antibody sabatolimab in myelodysplastic syndromes after failed phase 3 trial.
Fierce Pharma
JANUARY 31, 2024
AstraZeneca-partnered Enhertu has become a bright spot in Daiichi Sankyo’s business, and the Japanese pharma has again increased its sales projection for the HER2-directed antibody-drug conjugate.< | AstraZeneca-partnered Enhertu has become a bright spot in Daiichi Sankyo’s business, and the Japanese pharma keeps increasing its sales projections for the HER2-directed antibody-drug conjugate.
pharmaphorum
JANUARY 31, 2024
A surge in 2023 sales and profits fuelled by diabetes and obesity drugs has driven Novo Nordisk's valuation toward $500bn
Fierce Pharma
JANUARY 31, 2024
Even though Novartis grew sales and profits in the last quarter of 2023, the magnitude of the increases was not satisfactory to the Swiss pharma's investors. | Novartis grew sales and profits in the last quarter of 2023, but the magnitude of the increases was not satisfactory to the company’s investors. Among a portfolio of newer medicines, radiotherapy Pluvicto stuck out as a major drag.
Speaker: Simran Kaur, Founder & CEO at Tattva Health Inc.
The healthcare landscape is being revolutionized by AI and cutting-edge digital technologies, reshaping how patients receive care and interact with providers. In this webinar led by Simran Kaur, we will explore how AI-driven solutions are enhancing patient communication, improving care quality, and empowering preventive and predictive medicine. You'll also learn how AI is streamlining healthcare processes, helping providers offer more efficient, personalized care and enabling faster, data-driven
PharmaTech
JANUARY 31, 2024
This article introduces that the basic technique for tolerance interval is implemented using the conventional range 85–115% LC where the proposed range in the PF is not taken into account.
European Pharmaceutical Review
JANUARY 31, 2024
A combination of four 4,000-litre single-use bioreactors reaching a 16,000-litre scale has resulted in the successful completion of WuXi Biologics’ first manufacturing run at its drug substance facility MFG7 in Ireland. This is the largest manufacturing scale for the contract research, development and manufacturing organisation’s (CRDMO) to date.
MedCity News
JANUARY 31, 2024
Point-of-care lung ultrasound – also known as lung POCUS – is a safer, more reliable alternative to X-ray in diagnosing pneumonia that provides information quickly. Yet it’s not widely considered the standard of care.
ALULA
JANUARY 31, 2024
This Black History Month, we celebrate African culture & history via Benjamin Banneker and Madam C. J. Walker for maintaining and pursuing a clear vision.
Advertisement
Every marketer knows how important it is to prove their efforts drive sales opportunities, but that’s easier said than done. When problems like sales and marketing misalignment, lack of data, and wasted efforts persist, marketers can’t measure, prove, or increase their impact on revenue at a time when demonstrating marketing value is critical. Using analyst and expert data, this guide to marketing impact and content attribution explains: How B2B buyers use content The most common types of conten
MedCity News
JANUARY 31, 2024
To succeed in ACO Reach, groups need to accurately identify the social determinants of health (SDoH) barriers affecting their patient population and determine which barriers could be addressed effectively. Some technology can accurately note specific SDoH risk factors facing a given patient and offer targeted intervention recommendations based on that patient’s unique SDoH risk factors.
ALULA
JANUARY 31, 2024
African culture and history offer wisdom for the world. This Black History Month, we celebrate powerful leaders who achieved lasting positive impact.
pharmaphorum
JANUARY 31, 2024
AbbVie’s CD20xCD3 bispecific antibody Tepkinly has been recommended by NICE for NHS use as a treatment for relapsed or refractory diffuse large B-cell lymphoma (DLBCL), an aggressive and fast-growing form of non-Hodgkin lymphoma. Tepkinly (epcoritamab) – the first medicine to emerge from AbbVie’s $3.9 billion alliance with Genmab signed in 2020 – can be used to treat adults with DLBCL whose cancer has returned or has not responded to at least two previous systemic treatments.
MedCity News
JANUARY 31, 2024
Being Health, a startup that launched last week, offers a care team that includes psychiatrists, psychotherapists, nurse anesthetists, functional medicine physicians, nutritionists, acupuncturists and care advocates. It serves patients both virtually and in person.
pharmaphorum
JANUARY 31, 2024
Digital health investments has halved for the second year in a row, according to a new report from CB Insights
ALULA
JANUARY 31, 2024
This Black History Month, we celebrate African culture & history via Althea Neale Gibson and Berry Gordy Jr for being great leaders by coaching others.
Pharmaceutical Technology
JANUARY 31, 2024
CMS’ CGT Access Model will see allow the agency to negotiate negotiate pricing and build a framework that expands access to treatments.
pharmaphorum
JANUARY 31, 2024
GSK's RSV vaccine Arexvy outsold Pfizer's Abrysvo last year, but fourth-quarter figures suggest the gap may be narrowing.
Advertisement
Quotas need to be hit. Revenue goals need to be met. This reality makes shortening sales onboarding time a top priority. Organizations with a standard onboarding process boost employee retention by 58% and increase productivity by 50%. Unfortunately, many companies struggle with inefficient processes that lead to high turnover and missed revenue opportunities.
MedCity News
JANUARY 31, 2024
Here is a selection of recent executive hires, promotions and layoffs occurring across the healthcare industry.
PharmaTech
JANUARY 31, 2024
The emergence of mRNA vaccines and cell and gene therapies have pushed innovation in analytical methods.
PharmaTimes
JANUARY 31, 2024
Over 10,000 pharmacies in England will be offering the new advanced service
PharmaTech
JANUARY 31, 2024
Effective analytics will eliminate failures, deviations, and non-conformances.
PharmaTimes
JANUARY 31, 2024
The institute is one of two UK laboratories wholly funded by the MRC
PharmaTech
JANUARY 31, 2024
Distek’s software update for the Opt-Diss–In-Situ Fiber Optic UV System for Dissolution Testing, Version 3.20, introduces enhancements designed to streamline the dissolution testing process and expand the system’s capabilities.
PharmExec
JANUARY 31, 2024
Aduhelm (aducanumab-avwa) was granted accelerated approval by the FDA in June 2021 despite misgivings from the agency's Peripheral and Central Nervous System Drugs Advisory Committee.
PharmaTech
JANUARY 31, 2024
Designed for processing high viscosity dispersions and suspensions, the ROSS line of Dual-Shaft Mixers are versatile systems utilized in the chemical, pharmaceutical, food, cosmetic, adhesive, coating, composite, and other industries.
Advertisement
Are your sellers unsure about using AI in their day-to-day workflows? Or are they eager to try but uncertain where to start? They might be asking: Which tasks are best suited for AI? How will using AI affect my relationship with my customers? With so many tools available, which ones are the most useful to me? To help answer these and other common questions about using AI during the sales cycle, we surveyed B2B sellers who were early adopters to get their insight and advice about how to use gen A
Expert insights. Personalized for you.
324 
Let's personalize your content